



2021 CLINICAL UPDATES IN ACUTE MYELOID LEUKEMIA & DIFFUSE LARGE B CELL LYMPHOMA

APLC is please to invite you to attend the Virtual Stand-Alone Symposium to be held on 29 March 2022 (Tuesday) at

TH	1700-1830
SG /MY /HK /TW	1800-1930
JP /SK	1900-2030
AU	2100-2230
UK	0900-1030 (UK daylight saving time)

INTRODUCTION TO APLC:

Asia-Pacific Leukemia Consortium (APLC) is a regional collaborative group of healthcare professionals and affiliate healthcare partners aiming to change the status quo in the management of leukemia and related diseases in the Asia Pacific region through clinical research, trials and education.

Regional representation includes Australia, China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan and Thailand.

Clinical Updates aims to provide comprehensive coverage of the latest clinically significant advances in the treatment and management of leukemia and lymphoma as well as providing some insights to perspectives in the Asia-Pacific region. This inaugural meeting will focus on Acute Myeloid Leukemia (AML) & Diffuse Large B-Cell Lymphoma (DLBCL) featuring leading experts of the field Prof Andrew Wei (AU) & Prof Andrew Davies (UK). This session will be moderated by Profs Goh Yeow Tee and Kim Jin-Seok.

SGT Time	Agenda	Speaker/Moderator
1800-1810	Welcome address and introduction to APLC	Goh Yeow Tee
1810-1830	2021 Updates in Acute Myeloid Leukemia	Andrew Wei
1830-1845	Q&A	Andrew Wei / Goh Yeow Tee
1845-1905	2021 Updates in Diffused Large B-Cell Lymphoma	Andrew Davies
1905-1920	Q&A	Andrew Davies / Kim Jin-Seok
1920-1930	Concluding Remarks	Goh Yeow Tee

SPEAKERS



Prof Andrew Wei
The Alfred Hospital

Professor Andrew Wei is a haematologist and the Head of Leukemia Research at the Alfred Hospital.

After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, Prof Wei joined the Alfred Hospital in 2008 to develop the Acute Myeloid Leukaemia (AML) research program.

He is the Chairperson for the Australasian Leukemia And Lymphoma Group, Victorian Cancer Agency Research Fellow and Adjunct Associate Professor for Australian Centre For Blood Diseases.

Prof Wei is also an Executive Member of the ALLG Scientific Advisory Committee, and a member of the National Medical And Scientific Advisory Committee of the Leukaemia Foundation of Australia. He sits on the International Steering Committee for Celgene, providing expert advice on AML.



Prof Andrew Davies
University of Southampton

Prof Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton.

Prof. Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first in man lymphoma studies.

He is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.

CHAIRPERSON / CO-CHAIRPERSON:



Prof Goh Yeow Tee
Singapore General Hospital

Professor Goh Yeow Tee is currently Group Director, Research (Research Integrity, Compliance and Ethics) at SingHealth. He is also a Senior Consultant and Group Lead for Lymphoma and Myeloma at Singapore General Hospital. His previous positions include Acting Chairman for Division of Research, Director of Clinical Trials and Research Centre (CTRC), Director of Department of Clinical Research, Director of Office of Translational Medicine Oversight (TMO) and Director of Research Quality Management.

Prof Goh is an active researcher with interests in cell and immunotherapy, transplantation and clinical trials with early phase and novel agents for various hematologic malignancies. He has been recipient of more than S\$15 million in research grants and Principal Investigator for more than 70 trials.

Finally, he is a Founding Member of the Singapore Bone Marrow Donor Foundation as well as the Leukaemia Lymphoma Foundation.



Prof Kim Jin-Seok
Yonsei University College of Medicine,
Severance Hospital

Professor Kim is hematologist at Yonsei University College of Medicine, Severance Hospital. He graduated from Yonsei University College of Medicine in 1996. He earned his PhD from Yonsei University College of Medicine in 2004. He conducted research abroad at NHLBI, NIH and Clinical Center of NIH, Bethesda, MD, USA from 2012 to 2013.

His active research interest is lymphoproliferative disorders such as multiple myeloma or lymphoma and he conducted many clinical trials for multiple myeloma or lymphoma as a Principal Investigator.

He is currently a member of the International Myeloma Foundation's Asia Myeloma Network, the Korean Multiple Myeloma Working Party and Korean Lymphoma Working Party. Presently, he is working as a Director of Scientific Committee of the Korean Society of Hematology and an Associate Editor for the Blood Research.

Click on below link to register

<https://updatesbyaplc.klobbi.com>

Visit our website

www.sgh.com.sg/research-innovation/ACPs/Pages/Asia-Pacific-Leukemia-Consortium.aspx

Contact Email

lynn.wong.b.l@sgh.com.sg
APLC+Lowen@BeyondKairosSG.com

SPONSORS

abbvie

AMGEN®

